Fig. 2: HOXA9 low and high expression stratifies patients in AML.
From: HOXA9 has the hallmarks of a biological switch with implications in blood cancers
a HOXA9 expression in AML patients is significantly bimodal (unimodality test rejected with \(p \; < \; 2.2\times {10}^{-16}\)), suggesting a role as a genetic switch. The low peak consists of 31 patients for HOXA9 expression between 0.005–1 log (TPM+1) and 80 patients in the high peak –4–5.5 log(TPM + 1). b HOXA9 high and low cohorts have divergent AML prognosis, consistent with known HOXA9 biology in AML (log-rank test, p = 6 × 10−5). TPM transcript per million. Source data are provided as a Source Data file.
